2026-06-28T20:38:26Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1155142025-01-23T00:59:46Zcom_20.500.14352_14col_20.500.14352_15

Development of a Solid Formulation Containing a Microemulsion of a Novel Artemisia Extract with Nematocidal Activity for Oral Administration Perez-Roman, Inés Kiekens, Filip Córdoba Díaz, Damián García Rodríguez, Juan José Córdoba Díaz, Manuel Background: Intestinal nematode infections are usually treated with benzimidazole drugs, but the emergence of resistance to these drugs has led to an increasing demand of new anthelmintic strategies. A new microemulsion formulation (ME) consisting of an Artemisia absinthium extract with proven nematocidal efficacy was previously developed. The aim of our study is to implement a D-optimal mixture design methodology to increase the amount of a silica material (loaded with this ME) in a tablet formulation, considering its tensile strength and disintegration time. Methods: 16 experiments or combinations of the 6 tablet components (loaded silica, microcrystalline cellulose, polyvinylpyrrolidone, croscarmellose, Syloid® 244 FP and magnesium stearate) were assessed. Tensile strength and disintegration time models were developed, and an optimization process was carried out. Results: Tensile strength was improved by increasing the polyvinylpyrrolidone content, while croscarmellose decreased the disintegration time. The optimized powder mixture contains 49.7% w/w of the loaded silica material. A compression force of 12 kN was applied to the powder mixture to form tablets with a tensile strength of 2.0 MPa and a disintegration time of 3.8 min. Conclusions: Our results show that D-optimal mixture designs provide a promising approach to formulate liquid-loaded silica materials. 2025-01-22T09:43:15Z 2025-01-22T09:43:15Z 2020-09-14 journal article Perez-Roman I, Kiekens F, Cordoba-Diaz D, Garcia-Rodriguez JJ, Cordoba-Diaz M. Development of a Solid Formulation Containing a Microemulsion of a Novel Artemisia Extract with Nematocidal Activity for Oral Administration. Pharmaceutics. 2020 Sep 14;12(9):873. 10.3390/pharmaceutics12090873 https://hdl.handle.net/20.500.14352/115514 https://doi.org/10.3390/pharmaceutics12090873 eng open access MDPI